Hepsera (Gilead Sciences, Inc.)


Welcome to the PulseAid listing for the Hepsera drug offered from Gilead Sciences, Inc.. This Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Gilead Sciences, Inc.
NON-PROPRIETARY NAME: adefovir dipivoxil
SUBSTANCE NAME: ADEFOVIR DIPIVOXIL
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: TABLET
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2002-09-20
END MARKETING DATE: 0000-00-00


Hepsera HUMAN PRESCRIPTION DRUG Details:

Item DescriptionHepsera from Gilead Sciences, Inc.
LABELER NAME: Gilead Sciences, Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 10(mg/1)
START MARKETING DATE: 2002-09-20
END MARKETING DATE: 0000-00-00
PRODUCT ID: 61958-0501_22dc9759-59c6-4683-a461-6cdea36beabf
PRODUCT NDC: 61958-0501
APPLICATION NUMBER: NDA021449

Other ADEFOVIR DIPIVOXIL Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Excella GmbHHepsera
Gilead Sciences, Inc.Hepsera
Sigmapharm Laboratories, LLCADEFOVIR DIPIVOXIL